BiotechTube

eFT508

Phase 2Terminated
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Triple Negative Breast Cancer

Conditions

Triple Negative Breast Cancer, Hepatocellular Carcinoma

Trial Timeline

Nov 21, 2017 → Jan 22, 2019

NCT ID
NCT03318562

About eFT508

eFT508 is a phase 2 stage product being developed by eFFECTOR Therapeutics for Triple Negative Breast Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT03318562. Target conditions include Triple Negative Breast Cancer, Hepatocellular Carcinoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (3)

NCT IDPhaseStatus
NCT03690141Phase 2Terminated
NCT03318562Phase 2Terminated
NCT02605083Phase 1/2Terminated

Competing Products

20 competing products in Triple Negative Breast Cancer

See all competitors
ProductCompanyStageHype Score
BBI-355 + Erlotinib + Futibatinib + BBI-825Boundless BioPhase 1
25
No drugDaiichi SankyoPre-clinical
23
Tivozanib Hydrochloride + paclitaxel + PlaceboAstellas PharmaPhase 2
52
EnzalutamideAstellas PharmaPhase 2
52
Abemaciclib + BicalutamideEli LillyPhase 2
52
Camrelizumab + Apatinib + Nab-paclitaxel + Epirubicin + CyclophosphamideJiangsu Hengrui MedicinePhase 2
52
Camrelizumab Plus Chemotherapy + placebo+chemotherapyJiangsu Hengrui MedicinePhase 3
77
Camrelizumab + Nab-Paclitaxel + CarboplatinJiangsu Hengrui MedicinePhase 2/3
65
Fluzoparib+Paclitaxel + Epirubicin+CyclophosphamideJiangsu Hengrui MedicinePhase 2
52
Camrelizumab + Nab paclitaxel + Epirubicin + CyclophosphamideJiangsu Hengrui MedicinePhase 2
52
SHR-1210 + Apatinib +FluzoparibJiangsu Hengrui MedicinePhase 1
33
Cyclophosphamide + Placebo + Doxorubicin + Paclitaxel + Carboplatin + Veliparib + PlaceboAbbViePhase 3
77
Combination of Veliparib + LapatinibAbbViePre-clinical
23
Capivasertib + ItraconazoleAstraZenecaPhase 1
33
Datopotamab Deruxtecan (Dato-DXd) + DurvalumabAstraZenecaPhase 2
52
Paclitaxel + Carboplatin + MEDI4736 + MEDI9447AstraZenecaPhase 1/2
41
KU-0059436 (AZD2281)(PARP inhibitor) + Carboplatin + KU-0059436 (AZD2281)(PARP inhibitor) + Paclitaxel + KU-0059436 (AZD2281)(PARP inhibitor) + Paclitaxel + CarboplatinAstraZenecaPhase 1
33
Capivasertib + Paclitaxel + PlaceboAstraZenecaPhase 3
77
Olaparib Oral Product + Olaparib Oral Product in combination with DurvalumabAstraZenecaPhase 2
52
Durvalumab + Capivasertib + Oleclumab + Paclitaxel + Trastuzumab deruxtecan + Datopotamab deruxtecanAstraZenecaPhase 1/2
41

Other Products from eFFECTOR Therapeutics

Alpelisib + Tamoxifen + Zotatifin + FulvestrantPhase 2
44
eFT508Phase 2
44
eFT508 + AvelumabPhase 2
44
Tomivosertib (eFT-508)Phase 2
44
Letrozole + Abemaciclib + LY3023414 + Metformin + Zotatifin + GedatolisibPhase 2
44